Compare STEM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | GANX |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.9M | 159.2M |
| IPO Year | 2020 | 2021 |
| Metric | STEM | GANX |
|---|---|---|
| Price | $10.37 | $2.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $14.60 | $8.00 |
| AVG Volume (30 Days) | 169.2K | ★ 592.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.95 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $144,584,000.00 | $55,180.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | $12.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.29 | $1.41 |
| 52 Week High | $32.23 | $4.34 |
| Indicator | STEM | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 64.25 |
| Support Level | $0.38 | $1.56 |
| Resistance Level | $21.86 | $3.06 |
| Average True Range (ATR) | 0.79 | 0.18 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 6.62 | 82.59 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.